Experimental Talazoparib Better Than Chemo for HER2-, BRCA+ Mets

Options
Moderators
Moderators Member Posts: 25,912

Experimental Talazoparib Seems Better Than Chemotherapy for Metastatic HER2-Negative Disease in Women With a BRCA Mutation
December 20, 2017

The targeted therapy talazoparib resulted in longer progression-free survival compared to chemotherapy in women with a BRCA1 or BRCA2 mutation diagnosed with metastatic HER2-negative breast cancer. Read more...

Categories